The Use of the Isolated Mouse Whole Bladder for Investigating Bladder Overactivity
- The Oxford Continence Group, Department of Pharmacology, University of Oxford, Oxford, United Kingdom
- Address correspondence to:
Adebola C. Fabiyi, Oxford Continence Group, University Department of Pharmacology, Mansfield Road, Oxford OX1 3QT, UK. E-mail: adebola.fabiyi{at}nds.ox.ac.uk
Abstract
The isolated mouse whole bladder was used to study in vitro bladder overactivity evoked by intramural nerve sensitization with bradykinin, mimicking neurogenic bladder overactivity secondary to bladder inflammation. Intravesical pressure responses to intramural electrical stimulation of intramural nerves were measured under isovolumetric condition. Validation showed that carbachol produced a dose-response curve closely mirroring that observed in the isolated muscle strips and demonstrated the dual nature of electrically evoked neurotransmission, consisting of a cholinergic component largely mediated by M3 receptors and a purinergic component mediated by P2X receptors. ATP generated a biphasic dose-response curve, suggesting that the P2X receptors may be heterogeneous in distribution. Characterization of bradykinin receptors showed bradykinin to be extremely potent in exciting the bladder, producing a dose-response curve with an EC50 of 90 nM, and bradykinin also enhanced electrically evoked bladder contractions. These effects were inhibited by the B2 receptor antagonist HOE 140 (d-Arg0-Arg1-Pro2-Hyp3-Gly4-Thi5-Ser6-d-Tic7-Oic8-Arg9) but not the B1 receptor antagonist desArg10 HOE 140 (H-d-Arf-Arg-Pro-Hyp-Gly-Thi-Ser-d-Tic-Oic-OH) and were also modulated by α,β,methyleneATP. The isolated mouse whole bladder has proved a viable, robust model in which to demonstrate the pharmacological characteristic of the bladder and adds to the repertoire of in vitro tools for investigating potential therapeutic agents.
Footnotes
-
This work was supported by Abbot Laboratories.
-
Article, publication date, and citation information can be found at http://jpet.aspetjournals.org.
-
doi:10.1124/jpet.106.108902.
-
ABBREVIATIONS: EFS, electrical field stimulation; PW, pulse width; TD, train duration; CCh, carbachol; TTX, tetrodotoxin; pirenzepine, 5,11-dihydro-11-[(4-methyl-1-piperazinyl)acetyl]-6H pyrido[2,3-b] [1,4] benzodiacepin-6-one dihydrochloride; AF-DX116, 11–2[([(diethylamino) methyl]-1-piperidinyl)-acetyl]-5,11-dihydro-6Hpyrido(2,3b)(1,4)benzodiazepine-one; 4-DAMP, 4-diphenylacetoxy-N-methylpiperidine methobromide; PD102807, (3,6a,11,14-tetrahydro-9-methoxy-2-methyl-12H-isoquino[1,2-b]pyrrolo[3,2f][1,3]benzoxazine-1-carboxylic acid ethyl ester); p-F-HHSiD, para-fluoro hexahydrosiladifenidol; desArg10 HOE 140, H-d-Arf-Arg-Pro-Hyp-Gly-Thi-Ser-d-Tic-Oic-OH; HOE 140, d-Arg0-Arg1-Pro2-Hyp3-Gly4-Thi5-Ser6-d-Tic7-Oic8-Arg9; DMSO, dimethyl sulfoxide; ANOVA, analysis of variance.
-
- Received June 2, 2006.
- Accepted August 28, 2006.
- The American Society for Pharmacology and Experimental Therapeutics



